Payment overview · 2025
General Payments
$800.66
38 reported records · 6 companies
Healthcare provider profile · identity verified
Linsey Philip, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Infectious Disease · FALL RIVER, MA · NPI 1053304469
Verified facts
What the public records show
CMS Open Payments records show Linsey Philip, M.D. received $800.66 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 29.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Dovato, Farxiga, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Farxiga by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Descovy by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Ozempic by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $234.78 | 29.3% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $191.26 | 23.9% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $178.50 | 22.3% | 12 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $167.11 | 20.9% | 7 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $14.57 | 1.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.44 | 1.8% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $800.66 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $215.86 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $178.50 | 12 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $170.65 | 9 | 2025 |
Source payment records
|
|||||
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $132.31 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $118.14 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $99.22 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.16 | 3 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $14.57 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.44 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $6.36 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 65 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 80 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
65 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
85 | 13 |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
80 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 499 | 156 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 106 |
| Omeprazole | Omeprazole | 303 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 269 | 76 |
| Alprazolam | Alprazolam | 267 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 248 | 71 |
| Tramadol Hcl | Tramadol Hcl | 244 | 52 |
| Furosemide | Furosemide | 241 | 82 |
| Lisinopril | Lisinopril | 217 | 72 |
| Lorazepam | Lorazepam | 215 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 205 | 69 |
| Prednisone | Prednisone | 203 | 128 |
| Irbesartan | Irbesartan | 186 | 64 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 173 | 49 |
| Zolpidem Tartrate | Zolpidem Tartrate | 172 | 32 |
| Azithromycin | Azithromycin | 171 | 130 |
| Carvedilol | Carvedilol | 161 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 45 |
| Alendronate Sodium | Alendronate Sodium | 146 | 44 |
| Allopurinol | Allopurinol | 146 | 49 |
| Gabapentin | Gabapentin | 137 | 36 |
| Metformin Hcl | Metformin Hcl | 135 | 45 |
| Losartan Potassium | Losartan Potassium | 130 | 40 |
| Sertraline Hcl | Sertraline Hcl | 127 | 37 |
| Simvastatin | Simvastatin | 120 | 37 |
| Eliquis | Apixaban | 113 | 32 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 70 |
| Fluticasone Propionate | Fluticasone Propionate | 107 | 46 |
| Ibuprofen | Ibuprofen | 98 | 33 |
| Trazodone Hcl | Trazodone Hcl | 98 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 94 | 23 |
| Farxiga | Dapagliflozin Propanediol | 88 | 19 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 86 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 30 |
| Ozempic | Semaglutide | 85 | 13 |
| Dovato | Dolutegravir Sodium/Lamivudine | 80 | 11 |
| Spironolactone | Spironolactone | 78 | 25 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 76 | 33 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 75 | 53 |
| Glimepiride | Glimepiride | 75 | 27 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 19 |
| Jardiance | Empagliflozin | 71 | 19 |
| Ezetimibe | Ezetimibe | 70 | 20 |
| Buspirone Hcl | Buspirone Hcl | 68 | 21 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 27 |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 65 | suppressed |
| Potassium Chloride | Potassium Chloride | 64 | 26 |
| Naproxen | Naproxen | 62 | 21 |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 62 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 60 | 20 |
| Montelukast Sodium | Montelukast Sodium | 60 | 19 |
| Xarelto | Rivaroxaban | 60 | 17 |
| Cephalexin | Cephalexin | 59 | 35 |
| Valacyclovir | Valacyclovir Hcl | 57 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 56 | 11 |
| Levofloxacin | Levofloxacin | 54 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 50 | 24 |
| Clonazepam | Clonazepam | 49 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 21 |
| Finasteride | Finasteride | 45 | 15 |
| Warfarin Sodium | Warfarin Sodium | 45 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Levetiracetam | Levetiracetam | 43 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Famotidine | Famotidine | 41 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 12 |
| Meloxicam | Meloxicam | 40 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 38 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 37 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 36 | 12 |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Vascepa | Icosapent Ethyl | 36 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 18 |
| Fluconazole | Fluconazole | 33 | 24 |
| Metronidazole | Metronidazole | 33 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 32 | suppressed |
| Nystatin | Nystatin | 31 | 15 |
| Synthroid | Levothyroxine Sodium | 31 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 30 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Atenolol | Atenolol | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Clotrimazole | Clotrimazole | 25 | 11 |
| Entresto | Sacubitril/Valsartan | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Temazepam | Temazepam | 21 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 11 |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 14 |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 18 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Oxycontin | Oxycodone Hcl | 18 | suppressed |
| Prezcobix | Darunavir/Cobicistat | 18 | suppressed |
| Sotalol | Sotalol Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Lactulose | Lactulose | 16 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Delstrigo | Doravirine/Lamivu/Tenofov Diso | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Pifeltro | Doravirine | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Alphagan P | Brimonidine Tartrate | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Descovy | Emtricitabine/Tenofov Alafenam | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $800.66 · 38 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Biktarvy, DOVATO, FARXIGA, Ozempic, REXULTI, Rybelsus, VOQUEZNA, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error